Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but most tumors show resistance. Resistance is connected to a non-T cell inflamed phenotype partially caused by a lack of functional dendritic cells (DCs) that are crucial for T cell priming. Herein, we investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenthe, Jessica, Naseri, Sedigheh, Hellström, Ann-Charlotte, Moreno, Rafael, Ullenhag, Gustav, Alemany, Ramon, Lövgren, Tanja, Eriksson, Emma, Loskog, Angelica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810301/
https://www.ncbi.nlm.nih.gov/pubmed/35141399
http://dx.doi.org/10.1016/j.omto.2022.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810301/
https://www.ncbi.nlm.nih.gov/pubmed/35141399
http://dx.doi.org/10.1016/j.omto.2022.01.003

Ejemplares similares